4 quarters tracked · Beat rate 75% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q3 2026 | 2026-03-31 | $2.82 | $2.86 | +1.3% | Beat |
| Q2 2026 | 2025-12-31 | $2.75 | $2.81 | +2.1% | Beat |
| Q1 2026 | 2025-09-30 | $2.58 | $2.55 | -1.2% | Miss |
| Q1 2001 | 2000-09-30 | $0.04 | $0.05 | +16.6% | Beat |
Earnings Beat Rate
ResMed has beaten analyst EPS estimates in 3 of 4 tracked quarters (75% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →